Study guide
Stargardt, Best disease and retinal electrophysiology
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
Stargardt, Best disease and retinal electrophysiology
Key Takeaways Explain This Topic AI
ABCA4-associated disease affects retinoid handling, while BEST1 disease has a different mechanism and test pattern.
ERG and EOG assess different retinal functions and must be interpreted with laboratory standards.
A delayed VEP can support pathway dysfunction but is not uniquely diagnostic of optic neuritis or multiple sclerosis.
Last updated: October 2026
Stargardt Disease & Fundus Flavimaculatus
Stargardt disease is the most common hereditary juvenile macular dystrophy, with a prevalence of approximately 1 in 8,000 to 10,000 individuals. It is inherited almost exclusively as an autosomal recessive trait caused by bi-allelic pathogenic variants in the ABCA4 gene located on chromosome 1p22. When the condition manifests with widespread flecks extending into the mid-periphery in adult life, it is historically designated fundus flavimaculatus .
The ABCA4 Biochemical Cascade and A2E Lipofuscin Toxicity
The ABCA4 gene encodes an ATP-binding cassette transporter (historically termed the "rim protein") localized specifically to the outer segment disc margins of both rod and cone photoreceptors:
The Normal Visual Cycle Flippase: Upon photostimulation, rhodopsin photoisomerizes 11-cis-retinal into all-trans-retinal. Free all-trans-retinal reacts with phosphatidylethanolamine (PE) inside the disc lumen to form N-retinylidene-phosphatidylethanolamine (N-ret-PE). ABCA4 acts as an ATP-dependent flippase , actively transporting N-ret-PE across the disc membrane from the luminal leaflet to the cytoplasmic leaflet. In the cytoplasm, all-trans-retinal dissociates and is reduced to all-trans-retinol by retinol dehydrogenase.
Flippase Failure & A2E Synthesis: In ABCA4 deficiency, N-ret-PE is trapped within the disc lumen. Trapped N-ret-PE non-enzymatically condenses with a second molecule of all-trans-retinal to generate A2E (pyridinium bisretinoid) and related toxic bisretinoid fluorophores.
Lysosomal RPE Poisoning: When photoreceptor outer segments are routinely shed and phagocytosed by RPE cells, A2E cannot be degraded by lysosomal enzymes. A2E accumulates as toxic, fluorescent lipofuscin granules within RPE lysosomes. A2E exhibits detergent-like properties that permeabilize lysosomal membranes, impairs the RPE Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump, and releases reactive oxygen species upon blue light exposure ( 400 − 480 nm 400-480\,\text{nm} 400 − 480 nm ), culminating in apoptotic RPE death followed by secondary photoreceptor atrophy.
Clinical Presentation & Multimodal Diagnostics
Presentation: Bilateral, symmetric, progressive reduction in central distance and near visual acuity typically presenting between ages 8 and 15 years (often dropping to 6 / 60 6/60 6/60 [ 20 / 200 20/200 20/200 ]), frequently accompanied by central scotomas and dyschromatopsia. In early stages, visual acuity loss is characteristically disproportionate to the subtle macular changes, often leading to erroneous suspicions of non-organic (functional) visual loss.
Macular Appearance: Early loss of the foveal reflex evolves into a granular, "snail-slime" or oval "beaten-bronze" appearance of central RPE atrophy, progressing to well-circumscribed geographic foveal atrophy.
Pisciform Flecks: Yellowish-white, fish-tail-shaped (pisciform) or triradiate lesions situated at the level of the RPE. Flecks undergo a dynamic lifecycle: active flecks appear intensely hyperautofluorescent, then gradually fade over years to leave round, hypoautofluorescent atrophic scars.
Diagnostic Multimodal Imaging:
Fundus Autofluorescence (FAF): The single most sensitive and characteristic diagnostic investigation! Active pisciform flecks exhibit intense hyperautofluorescence (representing A2E lipofuscin accumulation within stressed RPE cells). In the fovea, RPE cell death creates a sharply demarcated, round or oval zone of profound hypofluorescence (a jet-black patch of macular atrophy) .
Fluorescein Angiography (FA): Displays the characteristic "dark choroid" (or "silent choroid" ), present in approximately 85% of Stargardt patients . The massive accumulation of lipofuscin throughout the entire RPE monolayer strongly absorbs the blue excitation wavelengths ( 465 − 490 nm 465-490\,\text{nm} 465 − 490 nm ), blocking underlying choroidal fluorescence during the early transit phase. Retinal vessels stand out in sharp contrast against a completely black, non-fluorescent choroid. In the macula, central RPE atrophy produces a bright transmission window defect.
SD-OCT: Demonstrates early loss of the foveal ellipsoid zone (EZ band) and external limiting membrane, thinning of the outer nuclear layer, and late complete excavation of the foveal RPE and neurosensory retina.
Counselling : Avoid unnecessary high-dose vitamin A supplements in ABCA4 disease, while maintaining normal nutrition and treating proven deficiencies appropriately. UV protection and rehabilitation can help; special blue-blocking lenses are not a proven cure or progression guarantee.
Best Vitelliform Macular Dystrophy (Best Disease)
Best disease (vitelliform macular dystrophy) is an autosomal dominant condition with variable penetrance and expressivity, caused by heterozygous pathogenic variants in the BEST1 gene located on chromosome 11q12.
Molecular Genetics & Pathogenesis
The BEST1 gene encodes bestrophin-1 , a homopentameric transmembrane calcium-activated chloride channel localized exclusively to the basolateral plasma membrane of the retinal pigment epithelium . Dysfunctional bestrophin-1 disrupts chloride and fluid conductance across the basolateral RPE membrane, uncoupling normal fluid resorption from the subretinal space. As a consequence, unphagocytosed photoreceptor outer segment debris, lipofuscin fluorophores, and fluid accumulate abnormally between the apical microvilli of the RPE and the photoreceptor outer segments.
The Five Clinical Stages of Best Disease
Stage 1 (Pre-Vitelliform): Normal funduscopy or subtle, tiny yellow foveal punctate dots in an asymptomatic child or infant. Visual acuity is entirely normal ( 6 / 6 6/6 6/6 / 20 / 20 20/20 20/20 ). Crucially, the electro-oculogram (EOG) is already severely subnormal .
Stage 2 (Vitelliform): Characterized by a sharply circumscribed, elevated, round, dome-shaped, bright yellow-orange subretinal lesion (typically 1 to 2 disc diameters in size) centered precisely on the fovea, mimicking an "egg-yolk" (sunny-side up) . Usually presents between ages 3 and 15 years. Paradoxically, best-corrected visual acuity is remarkably well preserved (typically 6 / 6 6/6 6/6 to 6 / 12 6/12 6/12 / 20 / 20 20/20 20/20 to 20 / 40 20/40 20/40 ), despite the striking anatomical lesion.
Stage 3 (Pseudohypopyon): The yellow vitelliform material partially liquefies, settling gravitationally into the dependent, inferior half of the subretinal cavity to create a horizontal fluid line mimicking a hypopyon. Often observed in adolescents when changing posture. Visual acuity remains relatively stable.
Stage 4 (Vitelliruptive / "Scrambled Egg"): The vitelliform blister ruptures, fragmenting into an irregular, heterogeneous constellation of scrambled yellow debris, pigmented clumping, and localized fluid. Visual acuity begins to decline significantly ( 6 / 18 6/18 6/18 to 6 / 36 6/36 6/36 ).
Stage 5 (Atrophic / Cicatricial): The vitelliform material is completely resorbed, leaving a central patch of geographic RPE and photoreceptor atrophy. In approximately 20% of eyes , this stage is complicated by secondary subretinal choroidal neovascularisation (CNV) , producing a fibrous disciform scar with visual acuity dropping to ≤ 6 / 60 \le 6/60 ≤ 6/60 ( 20 / 200 20/200 20/200 ). Secondary CNV responds favourably to intravitreal anti-VEGF therapy.
The Diagnostic Hallmark: EOG vs. ERG
The definitive diagnostic hallmark of Best disease—and a premier testing point on the EBOD—is the striking dissociation between the electro-oculogram and the full-field electroretinogram:
The Electro-oculogram (EOG): characteristically usually subnormal, but sometimes normal in genetically confirmed disease (as well as in asymptomatic, gene-positive carriers). The Arden ratio is severely attenuated: Arden Ratio = Light Peak Amplitude Dark Trough Amplitude < 1.5 ( Normal: > 1.85 to 2.0 ) \text{Arden Ratio} = \frac{\text{Light Peak Amplitude}}{\text{Dark Trough Amplitude}} < 1.5 \quad (\text{Normal: } > 1.85 \text{ to } 2.0) Arden Ratio = Dark Trough Amplitude Light Peak Amplitude < 1.5 ( Normal: > 1.85 to 2.0 )
Full-Field Electroretinogram (ffERG): Completely NORMAL across all scotopic and photopic flash responses. Because the bestrophin-1 defect is restricted to basolateral RPE chloride transport, mass photoreceptor and bipolar electrical activity across the wider retina remains intact.
Retinal Electrophysiology: ISCEV Standards
The International Society for Clinical Electrophysiology of Vision (ISCEV) has standardized the administration and reporting of visual electrophysiology:
1. Full-Field Electroretinogram
The full-field ERG measures summed retinal responses and can be abnormal with preserved macular acuity. ISCEV 2022 specifies six standard responses: dark-adapted 0.01, 3 and 10 ERGs; dark-adapted 3 or 10 oscillatory potentials; light-adapted 3 ERG; and light-adapted 30-Hz flicker. Standard dark adaptation is at least 20 minutes and light adaptation at least 10 minutes. The weak dark-adapted response mainly assesses the rod pathway; strong dark-adapted flashes assess mixed rod/cone pathways, and photopic responses assess cone pathways. The a-wave predominantly reflects photoreceptors and the b-wave post-receptoral activity, particularly bipolar cells. An electronegative response has a disproportionately small b-wave and suggests post-receptoral dysfunction, but is not one disease diagnosis.
2. Pattern Electroretinogram (PERG) & Visual Evoked Potential (VEP)
Pattern ERG (PERG): Elicited by an alternating high-contrast black-and-white checkerboard stimulus centered on the fovea, evaluating localized macular and ganglion cell function:
P50 Wave: Prominent positive deflection occurring at ~50 ms, reflecting macular function with substantial ganglion-cell contribution.
N95 Wave: Negative deflection occurring at ~95 ms, generated selectively by retinal ganglion cells ; attenuated in optic neuropathies and glaucoma, although P50 can also be affected depending on disease severity.
Visual Evoked Potential (VEP): Records cortical electrical potentials generated at the primary visual cortex (V1) over the occipital pole (Oz electrode) in response to visual stimuli:
Pattern-Reversal VEP: Standard modality assessing the integrity of the anterior visual pathways. Measures the P100 wave (major positive peak occurring at ≈ 100 ms \approx 100\,\text{ms} ≈ 100 ms ):
P100 interpretation: Pattern VEP assesses the pathway from retina to visual cortex. Compare laboratory age- and stimulus-specific reference values, interocular differences, waveform and technical quality; a single universal latency cutoff does not establish demyelination.
P100 interpretation: Pattern VEP assesses the pathway from retina to visual cortex. Compare laboratory age- and stimulus-specific reference values, interocular differences, waveform and technical quality; a single universal latency cutoff does not establish demyelination.